ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1116

The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System

Chio Yokose1, Baijun Zhou1, Natalie McCormick1, Sruthi Tanikella1, Minna Kohler2, Janeth Yinh1, Yuqing Zhang3 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, gout, hyperuricemia, metabolic syndrome, Renal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is recommended. Proactive use of SGLT2i among gout patients would have multiple benefits, including lowering the risk of HF and CKD progression, major adverse cardiovascular events (MACE), cardiovascular and all-cause mortality, in addition to their potential to lower serum urate and the risk of recurrent gout flares. We sought to examine the current state of SGLT2i use among gout patients with existing FDA-approved indications.

Methods: Using the Mass General Brigham (MGB) electronic health record, we identified two cohorts of gout patients with >1 gout-related encounter from 1/1/2021 to 1/4/2023 in the 1) Mass General Hospital rheumatology clinic (MGH rheum) or 2) anywhere within the MGB system (MGB gout). We used a combination of ICD codes, clinical variables, and laboratory values (Table 1) to determine the prevalence of FDA-approved indications for SGLT2i treatment: 1) T2DM and atherosclerotic cardiovascular disease (ASCVD); 2) T2DM and ASCVD risk factors; 3) T2DM and CKD; 4) CKD, defined as eGFR 20-44 mL/min/1.73m2 or 45-89 mL/min/1.73m2 with urinary albumin-to-creatinine ratio (UACR) ≥200 mg/g (regardless of T2DM); and 5) HF. We then determined the proportion of those patients with indications who were prescribed an SGLT2i.

Results: The MGH rheum and MGB gout cohorts included 1,212 and 21,301 gout patients, respectively (Table 2). The mean age was 64.9 and 68.1 years, respectively, and both groups were predominantly male. Of the patients in the MGH rheum and MGB gout cohorts, 41.8% and 45.6% had ≥1 FDA-approved indication for SGLT2i, respectively. However, only 10.7% and 9.7% of the patients with an SGLT2i indication (or 4.5% and 4.4% of the entire cohort) were actually prescribed one in the MGH rheum and MGB gout cohorts, respectively. The prevalence of SGLT2i indications was largely similar between the two cohorts. In both cohorts, CKD was the least prevalent indication at 16.2% and 16.0%, respectively. T2DM with ASCVD risk factors was the most prevalent indication in the MGB gout cohort at 28.4%, whereas T2DM with ASCVD risk factors and HF were similarly prevalent in the MGH rheum cohort at 23.7% and 23.8%, respectively. In both cohorts, T2DM with CKD was the indication for which the highest proportions of patients were appropriately prescribed an SGLT2i, although it still represented a minority of patients at 16.8% and 14.0%, respectively.

Conclusion: In this retrospective study from a large tertiary academic healthcare system, >40% of gout patients had ≥1 indication for SGLT2i. However, only about 10% of those with an indication for SGLT2i (or approximately 4.5% of the entire cohort) were prescribed one. Because SGLT2i have a myriad of proven cardiometabolic-kidney benefits, more proactive use of SGLT2i among patients with gout with an existing indication could improve their comorbidity outcomes and prevent premature mortality, while simultaneously yielding potential gout-related benefits. Future studies on the use of SGLT2i among gout patients are required, given the rapidly expanding indications for SGLT2i in cardiometabolic-kidney comorbidity care.

Supporting image 1

Supporting image 2


Disclosures: C. Yokose: None; B. Zhou: None; N. McCormick: None; S. Tanikella: None; M. Kohler: Mymee, 2, Springer Publications, 9; J. Yinh: None; Y. Zhang: None; H. Choi: Ani, 2, Horizon, 2, 5, LG, 2, Protalix, 2, Shanton, 2.

To cite this abstract in AMA style:

Yokose C, Zhou B, McCormick N, Tanikella S, Kohler M, Yinh J, Zhang Y, Choi H. The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-current-state-of-sodium-glucose-cotransporter-type-2-inhibitor-use-among-patients-with-gout-at-a-tertiary-academic-healthcare-system/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-current-state-of-sodium-glucose-cotransporter-type-2-inhibitor-use-among-patients-with-gout-at-a-tertiary-academic-healthcare-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology